LEADER 03544nam 2200637Ia 450 001 9910809514503321 005 20200520144314.0 010 $a1-282-86052-6 010 $a9786612860522 010 $a0-7735-7027-6 024 7 $a10.1515/9780773570276 035 $a(CKB)1000000000714093 035 $a(OCoLC)181843456 035 $a(CaPaEBR)ebrary10132417 035 $a(SSID)ssj0000283955 035 $a(PQKBManifestationID)11228062 035 $a(PQKBTitleCode)TC0000283955 035 $a(PQKBWorkID)10250682 035 $a(PQKB)10380198 035 $a(DE-B1597)654623 035 $a(DE-B1597)9780773570276 035 $a(VaAlCD)20.500.12592/gbtg2x 035 $a(schport)gibson_crkn/2009-12-01/1/400521 035 $a(MiAaPQ)EBC3330788 035 $a(MiAaPQ)EBC3244711 035 $a(EXLCZ)991000000000714093 100 $a20011214d2002 uy 0 101 0 $aeng 135 $aur||#|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aScience and social context $ethe regulation of recombinant bovine growth hormone in North America /$fLisa Nicole Mills 205 $a1st ed. 210 $aMontreal $cMcGill-Queen's University Press$dc2002 215 $a1 online resource (222 pages) 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a0-7735-2374-X 320 $aIncludes bibliographical references: p. [173]-204 and index. 327 $tFront Matter --$tContents --$tAcknowledgments --$tChronology --$tAcronyms --$tOverview --$tThe Economic Context: The Political Economy of Agricultural Biotechnology --$tThe Political Context in the United States --$tThe Political Context in Canada --$tThe Scientific Debate --$tConclusion --$tNotes --$tBibliography --$tIndex 330 $aShe examines the decision-making processes at Monsanto that led to their making the drug available and discusses corporate, academic, and regulatory decision-making in the context of a restructured global political economy for agriculture. Mills shows that there was consensus about the scientific evidence but interpretation of that evidence differed depending on the context from which it was viewed. Scientists who analysed it for regulatory bodies interpreted it differently than scientists in corporate or academic institutions, and scientists in Canada and Europe interpreted it differently than those in the United States. In the United States it was assumed that any problems arising from its use could be taken care of within the existing dairy system; in Canada and Europe these problems were regarded as legitimate animal welfare issues. While all regulatory bodies agreed that human health problems were unlikely, in Canada the Health Protection Branch questioned this, but ultimately rejected the drug on animal health grounds. 606 $aRecombinant bovine somatotropin$xGovernment policy$zUnited States 606 $aRecombinant bovine somatotropin$xGovernment policy$zCanada 606 $aRecombinant bovine somatotropin$xEconomic aspects$zCanada 615 0$aRecombinant bovine somatotropin$xGovernment policy 615 0$aRecombinant bovine somatotropin$xGovernment policy 615 0$aRecombinant bovine somatotropin$xEconomic aspects 676 $a636.2/0892405 700 $aMills$b Lisa Nicole$f1967-$01709203 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910809514503321 996 $aScience and social context$94198518 997 $aUNINA